Kinase Logistics Europe News
-
Offers
Discount on Kinases from Carna Biosciences!
Join us in celebrating another successful year with high-quality human Kinases from Carna Biosciences!
-
Offers
Carna’s Profiling Services Discount Campaign!
Carna’s Next-Gen Mobility Shift Assay (MSA) System supporting kinase drug discovery is now operational with scientific and budget friendly…
-
General
Next-generation Mobility Shift Assay Detection System!
We have great News for you: MSA is still accessible to your drug discovery research!
-
General
Biotinylated Kinases
We’ve new products for you: biologically biotinylated human Kinases from Carna Biosciences.
-
Offers
New Cellular CDK Assay Panel Launched and Special Offers from Carna
We are pleased to launch a new CDK (cyclin-dependent kinases) Cell-based Assay Panel for kinase researchers who are focusing on the CDK family.
… -
General
New Website Launch!
We’re extremely pleased to announce the launch of our new website!
We decided that it was time for a fresh new look, which surely empowers our…
Carna Biosciences Newsletter
-
Newsletter
Cancer treatments using inhibitors of CDK, a cell cycle regulator
Carna Newsletter Vol.16
-
Newsletter
ALK drug resistant mutations: Challenges for the treatment of lung cancer
Carna Newsletter Vol.15
-
Technical Note
DGKα and DGKζ are key targets for cancer immunotherapy
Carna Newsletter Vol.14
-
Newsletter
The potential of PIKfyve inhibitor as a treatment of amyotrophic lateral sclerosis (ALS)
Carna Newsletter Vol.13
-
Newsletter
The importance of understanding the activity of compounds on RAF dimerization in BRAF inhibitor drug discovery
Carna Biosciences Newsletter Vol. 12
-
Newsletter
Kinase Inhibitors as Potential Therapeutic Agents for COVID-19
Carna Biosciences Newsletter Vol. 11
-
Technical Note
Evaluating Kinase Inhibitors in Binding Assays using Activated and Non-Activated Biotinylated Kinases
Carna Biosciences Technical Note No. 1
-
Newsletter
Targeted Degradation of Non-catalytic Kinases New Drug Discovery Options
Carna Biosciences Newsletter Vol. 10
-
Newsletter
Drug-resistant EGFR mutations in lung cancer
Carna Biosciences Newsletter Vol. 9
-
Newsletter
Kinetic analysis of covalent and irreversible inhibitors
Carna Biosciences Newsletter Vol. 8
-
Technical Note
The importance of assessing intrinsic target kinase activity
Carna Biosciences Technical Note No. 2
-
Technical Note
Production of Highly Active Protein Kinases for Drug Discovery Applications
Carna Biosciences Technical Note No. 1
-
Newsletter
Kinase Inhibitors in the Fight against COVID-19
Carna Biosciences Newsletter Vol. 7
-
Newsletter
Recommendations for off-target profiling
Carna Biosciences Newsletter Vol. 6
-
Newsletter
The significance of ATP concentration in cell-free and cell-based assays
Carna Biosciences Newsletter Vol. 4
-
Newsletter
Targeted Protein Degraders
Carna Biosciences Newsletter Vol. 3
-
Newsletter
Residence time and compound selectivity
Carna Biosciences Newsletter Vol. 2
-
Newsletter
A story about biotin-avidin affinity and how it accelerates small molecule drug discovery
Carna Biosciences Newsletter Vol. 1